No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation. This compound is intended for patients suffering from chronic phase chronic myeloid leukemia that has become resistant to tyrosine kinase inhibitors. Beyond HQP1351, the company boasts a robust pipeline. This includes APG-2575 (Pelcitoclax), an orally administered, selective Bcl-2 inhibitor undergoing Phase Ib/II clinical studies for hematologic and solid tumors; APG-115 (Alrizomadlin), an oral small molecule designed to inhibit the MDM2-p53 protein-protein interaction for various solid and hematological malignancies; and APG-1387 (Nevadotinib), a small molecule inhibitor of apoptosis proteins targeting advanced solid tumors and chronic HBV infections. Further advancing its portfolio, Ascentage is developing APG-1252 (Atoloclab), a small molecule drug aimed at restoring apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins for conditions such as small cell lung cancer (SCLC), lymphoma, and other solid tumors. The pipeline also features APG-2449 (Glecirasib) for non-small-cell lung carcinoma (NSCLC); APG-5918, an orally available and selective EED inhibitor with best-in-class potential in its preclinical phase; APG-265, currently in IND-enabling stages for hematological and solid tumors; and UBX1967/1325, a Phase II candidate targeting the Bcl family for diabetic macular edema (DME). The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical companies, as well as academic institutions. Key partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Established in 2009, Ascentage Pharma is headquartered in Suzhou, China.
www.ascentage.cnNo one on the platform currently holds 6855.HK.
No tracked institution reports a position in 6855.HK as of their last filing.
No one on the platform has traded 6855.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -43.0% | 114.0% | ||||
| Profit Margin % | -216.5% | -779.8% | -2789.7% | |||
| Free Cash Flow Margin % | -214.9% | -943.4% | -2222.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $851M | +62.1% | $-1.94 | $-1.99–$-1.89 | — | 2 |
| 2027 | $1.9B | +126.2% | $-0.73 | $-2.15–$0.68 | — | 2 |
| 2028 | $2.7B | +38.9% | $-0.39 | $-0.95–$0.16 | — | 2 |
| 2029 | $5.8B | +118.6% | $0.96 | $0.45–$1.66 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-18 | $-0.43 | $-2.53 | -483.7% |
| 2026-03-24 | $-1.63 | $-1.25 | +23.4% |
| 2025-03-27 | $0.03 | $0.03 | +0.0% |
| $74.60 |
| -0.47% |
| $22.0B |
| — |
| 2171.HKCARsgen Therapeutics Holdings Limited | $12.48 | -2.04% | $7.1B | — |
| 3933.HKThe United Laboratories International Holdings Limited | $7.90 | -2.77% | $15.6B | — |
Source: Financial Modeling Prep · peers by sector/industry